学位：博士学位
学历：研究生(博士)毕业
职称：教授
所在单位：基础医学院
学术荣誉： 曾获荣誉：
中南大学教授，博士生/博士后导师，现任中南大学基础医学院病理学系/湘雅医院病理科副主任、分子病理诊断中心主任。病理学国家级精品课程主讲教师、病理学国家级资源共享课程主讲教师及基础医学形态学国家级教学团队、卫计委临床重点专科骨干成员，副主编及参编《病理学》全国高等学校医学规划教材及配套教材7本，人民卫生出版社国家医学教育题库病理学学科副主编，获校级教学成果奖8项；参与或主持了教育部教改项目、教育部修购专项资助项目、教育部985资助项目、国家自然科学基金及湖南省科技计划项目10项。发表本专业SCI论文90余篇。获湖南省自然科学奖三等奖一项。
Desheng Xiao, Ph.D., professor, PhD candidate/post-doctoral supervisor, Deputy Director of Department of Pathology, Basic Medical School/Xiangya Hospital, Central South University, Director of Molecular Pathology Diagnosis Center. The main teacher of national excellent pathology course and national resource sharing course, the national teaching team of basic medical Morphology, and the main member of National Health and Family Planning Commission key clinical specialty. Presided over or participated in 10 projects of national Natural Science Foundation of China and Natural Science Foundation of Hunan Province. Won the third prize of Natural Science award of Hunan Province (ranked the third). Published more than 90 SCI papers in this field. Concurrently hold the molecular pathology group member of the Chinese medical doctor association pathology branch, a member of the standing committee of the China medical equipment AI union pathology committee, the incoming chairman of hunan province medical association pathology professional committee, the chairman of hunan medical association pathology professional committee Younger Committee, the vice president of Hunan Medical Doctor Association Pathologist Branch, the vice director of hunan Clinicopathological Quality Control Center, a member of Hunan Anti-cancer Association Lung Cancer Professional Committee. and a review expert of the National Natural Science Foundation of China.
Decrease of TET2 expressionand increase of 5-hmC levels in myeloid sarcomas
点击次数：
影响因子：2.214
所属单位：中南大学
教研室：病理学系
发表刊物：Leukemia Research
关键字：5-hmC; CD34; CD68; Myeloid sarcoma; Myeloperoxidase; TET2.
摘要：Background: Myeloid sarcoma is a tumor mass that consists of myeloblasts or immature myeloid cells at an extramedullary site. Pathological diagnosis is very difficult based on morphology if systemic signs of disease are absent. The subtype of myeloid sarcoma is also minimally identifiable in the histological picture. Findings: We investigated 18 paraffin-embedded myeloid sarcoma samples, and our immunohistochemical data confirmed the relevance of some key markers for the diagnosis and subclassification of myeloid sarcoma. CD34 was found as a marker in 67% of the myeloid sarcoma cases, and CD34 was positive in all immature types of myeloid sarcoma. CD68 was found in 83% of the myeloid sarcoma cases, but CD68 was most identified in the differentiated type of myeloid sarcoma. Myeloperoxidase (MPO) was positive in all myeloid sarcomas. Notably, the reactivity of MPO in the blastic subtype was much lower in myeloid sarcomas. CD117 reactivity was found in 67% of myeloid sarcomas. Ten-eleven translocation 2 (TET2) protein exhibited significant negative reactivity in 88% of the cases, and 5-methylcytosine (5-hmC) was significantly positive in the nucleus in 100% of the cases. Conclusions: Our findings indicated that an immunohistochemical panel that included MPO, CD68 and CD34 could be used for the detection of blastic, differentiated and immature types of myeloid sarcoma. Changes in novel epigenetic regulators, including the loss of TET2 and gain of 5-hmC, as characteristics of myeloid malignancies may be useful novel markers of myeloid sarcoma.
合写作者：Ying Shi, Chunyan Fu, Jiantao Jia, Yu Pan, Yiqun Jiang, Ling Chen, Shuang Liu, Wen Zhou, Jianhua Zhou
第一作者：Desheng Xiao
论文类型：期刊论文
通讯作者：Yongguang Tao
卷号：42
页面范围：75-79
是否译文：否
发表时间：2016-01-12
收录刊物：SCI
